The Epidermal Growth Factor Receptor in Breast Cancer

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of mammary gland biology and neoplasia

• Publication date

  1997-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1023/A:1026399613946PMID 10882299
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proliferating cell nuclear antigen in breast lesions: Correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer

  2005cited by this paper
• The prognostic significance of epidermal growth factor receptor expression in breast cancer

  2005influential reference
• The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study

  2004cited by this paper
• Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients

  2004cited by this paper
• Epidermal growth factor receptor in breast cancer: Correlation of quantitative immunocytochemical assays to prognostic factors

  2004influential reference
• Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast

  2004cited by this paper
• The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status

  2004cited by this paper
• Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study

  2004cited by this paper
• The epidermal growth factor receptor as a target for therapy in breast carcinoma

  2004cited by this paper
• Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer

  2004cited by this paper
• Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy

  2004influential reference
• Mechanisms of EGF receptor regulation in breast cancer cells

  2004cited by this paper
• Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay — a retrospective study

  2004influential reference
• The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients

  2004cited by this paper
• Tumor angiogenesis in node-negative breast carcinomas — relationship with epidermal growth factor receptor, estrogen receptor, and survival

  2004cited by this paper
• Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study

  2004influential reference
• A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma

  2004influential reference
• Radiolocalization of squamous lung carcinoma with 131I-labeled epidermal growth factor.

  1996cited by this paper
• Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research

  1995cited by this paper
• Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas

  1995cited by this paper
• Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer.

  1995cited by this paper
• Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2.

  1995cited by this paper
• Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.

  1995cited by this paper
• Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms.

  1995cited by this paper
• Enhancement of drug sensitivity of human malignancies by epidermal growth factor.

  1995cited by this paper
• Epiregulin

  1995cited by this paper
• Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.

  1995cited by this paper
• A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation.

  1995cited by this paper
• Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas.

  1995cited by this paper
• Determination of the prognostic value of cyclin D1 overexpression in breast cancer.

  1995cited by this paper
• Gene methylation of oestrogen and epidermal growth factor receptors in neoplastic and perineoplastic breast tissues.

  1995cited by this paper
• Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.

  1995cited by this paper
• Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2.

  1995cited by this paper
• Topological Analysis of the Integral Membrane Protein, Type 1 Iodothyronine Deiodinase (D1) (*)

  1995cited by this paper
• Coexpression of TGF alpha, epidermal growth factor receptor, and P-glycoprotein in normal and benign diseased breast tissues.

  1995cited by this paper
• Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance.

  1995cited by this paper
• Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers.

  1995cited by this paper
• Anti‐tumor efficacy of an anti‐epidermal‐growth‐factor‐ receptor monoclonal antibody and its F(ab′)2 fragment against high‐ and low‐egfr‐expressing carcinomas in nude mice

  1995cited by this paper
• Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.

  1995cited by this paper
• Structure-function relationships for the EGF/TGF-alpha family of mitogens.

  1994cited by this paper
• Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer.

  1994cited by this paper
• bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.

  1994cited by this paper
• Selective toxicity of TGF-alpha-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF.

  1994cited by this paper
• Structure-Function relationships for the EGF/TGF-α family of mitogens

  1994cited by this paper
• High expression of the EGFR in fibroadenomas compared to breast carcinomas.

  1994cited by this paper
• The prognostic value of epidermal growth factor receptor (EGFR) in breast cancer patients. Results of a follow-up study on 149 patients.

  1994influential reference
• Epidermal growth factor receptors in breast cancer: comparison of radioligand and immunocytochemical assays.

  1994cited by this paper
• Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients.

  1993cited by this paper
• Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.

  1993cited by this paper
• Prognostic factors and response to therapy in breast cancer.

  1993cited by this paper
• Amphiregulin, epidermal growth factor receptor, and estrogen receptor expression in human primary breast cancer.

  1993cited by this paper
• Epidermal growth factor receptor in breast cancer. Comparison with non malignant breast tissue.

  1993cited by this paper
• Erratum: “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,”

  1993cited by this paper
• The prognostic significance of transforming growth factors in human breast cancer.

  1993cited by this paper
• Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer.

  1992cited by this paper
• Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.

  1992cited by this paper
• Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases.

  1992cited by this paper
• The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.

  1992cited by this paper
• Epidermal growth factor receptors in human breast cancer: a plea for standardisation of assay methodology.

  1992cited by this paper
• Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma.

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• Immunocytochemistry and in situ hybridisation of epidermal growth factor receptor and relation to prognostic factors in breast cancer.

  1992influential reference
• Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.

  1992cited by this paper
• p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.

  1992cited by this paper
• Prognostic value of epidermal growth factor receptor in a series of 303 breast cancers.

  1992cited by this paper
• Synthetic oligonucleotides as therapeutic agents.

  1991influential reference
• Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer

  1991cited by this paper
• Epidermal growth factor receptors in intracranial and breast tumours: their clinical significance.

  1991cited by this paper
• Epidermal growth factor receptor expression as a prognostic indicator in breast cancer.

  1991cited by this paper
• Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer.

  1991influential reference
• Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.

  1991cited by this paper
• Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers.

  1991cited by this paper
• IMMUNOHISTOCHEMICAL EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR IN BENIGN AND MALIGNANT LESIONS OF THE BREAST

  1991cited by this paper
• Expression of epidermal growth factor receptor in breast carcinoma.

  1990influential reference
• Estimation of epidermal growth factor receptor in 177 breast cancers: Correlation with prognostic factors

  1990cited by this paper
• What is the evidence that tumors are angiogenesis dependent?

  1990cited by this paper
• Epidermal growth factor receptor in human breast cancer: correlation with cytosolic and nuclear ER receptors and with biological and histological tumor characteristics.

  1990influential reference
• Epidermal growth factor receptors and prognosis in primary breast cancer

  1990cited by this paper
• A Hitchhiker’s Guide to the NIEHS Strategic Plan

  1990cited by this paper
• Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast

  1990cited by this paper
• neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues.

  1990cited by this paper
• Tyrphostins--potential antiproliferative agents and novel molecular tools.

  1990cited by this paper
• [Receptors for epidermal growth factor in breast cancer].

  1990influential reference
• An inducible endothelial cell surface glycoprotein mediates melanoma adhesion.

  1989cited by this paper
• Growth factor expression in normal, benign, and malignant breast tissue

  1989cited by this paper
• Prognostic value of epidermal growth factor receptor in node-positive breast cancer

  1989cited by this paper
• Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.

  1989cited by this paper
• Epidermal growth factor receptor in human breast cancer.

  1989cited by this paper
• Targeted toxin therapy for the treatment of cancer.

  1989cited by this paper
• Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.

  1989cited by this paper
• Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer.

  1989cited by this paper
• Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma.

  1988cited by this paper
• Epidermal growth factor receptor in human breast cancers: Correlation with estrogen and progesterone receptors

  1988cited by this paper
• Growth factor expression in normal, benign, and malignant breast tissue

  1988cited by this paper
• Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer.

  1988cited by this paper
• Predictive value of EGF receptor in breast cancer.

  1988cited by this paper
• P53 expression in breast cancer

  1988cited by this paper

• Lymph Node Status: In Reply to Carr.

  2019cites this paper
• Recent Advancements Involving Immunoliposomes to Target Breast Cancer

  2018cites this paper
• Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer

  2016cites this paper
• mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer

  2015cites this paper
• Stiff substrates increase YAP-signaling-mediated matrix metalloproteinase-7 expression

  2015cites this paper
• The Role of Tumor Suppressor Co-Chaperone CHIP/STUB1 in ERBB2-Mediated Oncogenesis

  2015cites this paper
• Immunological Visibility: Posttranscriptional Regulation of Human NKG2D Ligands by the EGF Receptor Pathway

  2014cites this paper
• Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice

  2011cites this paper
• Epidermal Growth Factor Receptor in Triple-Negative and Basal-Like Breast Cancer: Promising Clinical Target or Only a Marker?

  2010cites this paper
• A Role For Lipid Rafts In Egfr Tki Resistance In Breast Cancer

  2010cites this paper
• Localised and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility

  2009cites this paper
• Expression and prognostic significance of the EGFR in solid tumors

  2008cites this paper
• Metabolite identification of a new antitumor agent icotinib in rats using liquid chromatography/tandem mass spectrometry.

  2008cites this paper
• Targeted Therapy For Breast Cancer

  2008cites this paper
• Prognostic Value of Signal Transducers and Activators of Transcription 3 in Breast Cancer

  2008cites this paper
• HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer

  2008cites this paper
• Quantitation of multisite EGF receptor phosphorylation using mass spectrometry and a novel normalization approach.

  2007cites this paper
• Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics

  2007cites this paper
• Signal transducer and activator of transcription 1 in breast cancer: analysis with tissue microarray.

  2007cites this paper
• Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer.

  2007cites this paper
• Epidermal Growth Factor Receptor Inhibition Modulates the Nuclear Localization and Cytotoxicity of the Auger Electron–Emitting Radiopharmaceutical 111In-DTPA–Human Epidermal Growth Factor

  2007cites this paper
• The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer

  2006cites this paper
• Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1α expression through activation of AKT and P70S6K1 in human ovarian cancer cells

  2006cites this paper
• "Basal-like" Breast Carcinomas: Identification by P-cadherin, P63 and EGFR Basal Cytokeratins Expression

  2006cites this paper
• Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

  2006cites this paper
• Erlotinib-Induced Breast Cancer Regression

  2006cites this paper
• Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells.

  2006cites this paper
• Hypoxia and angiogenesis in colorectal liver metastases

  2005influential citation
• Progesterone Pre-treatment Potentiates EGF Pathway Signaling in The Breast Cancer Cell Line ZR-75*

  2005cites this paper
• Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1.

  2005cites this paper
• Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

  2005cites this paper
• Aromatase Overexpression: Effect of Tissue Estrogen on Phenotypic and Biochemical Changes in Aromatase Transgenic Mice

  2005cites this paper
• Single-Dose Clinical Pharmacokinetic Studies of Gefitinib

  2005cites this paper
• Expression of nuclear hormone receptors, their coregulators and type I iodothyronine 5'-deiodinase gene in mammary tissue of nonlactating and postlactating rats.

  2005cites this paper
• Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells

  2005cites this paper
• Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.

  2004cites this paper
• CD47 Mediates Killing of Breast Tumor Cells via Gi-Dependent Inhibition of Protein Kinase A

  2004cites this paper
• Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications.

  2004cites this paper
• Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.

  2003cites this paper
• CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.

  2003cites this paper
• Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer

  2003cites this paper
• Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer.

  2003cites this paper
• New insights into estrogen receptor function in human breast cancer

  2003cites this paper
• Epidermal Growth Factor

  2002cites this paper
• Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression.

  2002cites this paper
• Hormone/growth factor interactions mediating epithelial/stromal communication in mammary gland development and carcinogenesis.

  2002cites this paper
• Molecular markers and therapeutic targets in ductal carcinoma in situ

  2002cites this paper
• Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release.

  2002influential citation
• Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase.

  2002cites this paper
• Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis.

  2002cites this paper
• Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.

  2002cites this paper
• Immunocytochemical Expression of Epidermal Growth Factor Receptor in Myoepithelial Cells of the Breast

  2002cites this paper
• Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

  2002cites this paper
• ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

  2002cites this paper
• In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment

  2002cites this paper
• Inhibición de la apoptosis y acúmulo de alteraciones genéticas en la progresión metastática del cáncer de mama: variabilidad genética y selección poblacional.

  2002cites this paper
• EGFR dependent expression of STAT3 (but not STAT1) in breast cancer.

  2001cites this paper
• Acceleration of mammary neoplasia in aromatase transgenic mice by 7,12-dimethylbenz[a]anthracene.

  2001cites this paper
• Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

  2000cites this paper
• The ErbB Receptors as Targets for Breast Cancer Therapy

  1999cites this paper
• Tissue structure, nuclear organization, and gene expression in normal and malignant breast.

  1999cites this paper
• Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.

  1999cites this paper
• Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up.

  1999cites this paper
• Induction of mammary carcinomas by N-methyl-N-nitrosourea in ovariectomized rats treated with epidermal growth factor.

  1999cites this paper
• Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis.

  1998cites this paper
• NRG-3 in human breast cancers: activation of multiple erbB family proteins.

  1998cites this paper
• Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology.

  1998cites this paper
• Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile.

  1998cites this paper